The French Authority for Health has issued a positive opinion to fund Carthera’s SONOBIRD study evaluating its blood-brain barrier opening implant SonoCloud-9. The funding will be made available ...

Paris, France-based Carthera is reporting that SonoCloud, its ultrasound-based medical device targeting a wide range of brain diseases, shows potential for treating patients with Alzheimer’s Disease ...

Carthera SA reported results from a pilot clinical trial to evaluate the safety and efficacy of its Sonocloud technology in patients with mild Alzheimer’s disease (AD). The results, published in ...

Carthera has received an orphan medical device status endorsement for its SonoCloud ultrasound system for treating brain disorders under a new pilot programme by the European Medicines Agency (EMA).

Paris, France, June 9, 2021 – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces preclinical results in the ...

First results demonstrate safety of transient repeated BBB opening with SonoCloud in Alzheimer’s patients, and show potential of technology as a new therapeutic approach for treatment of Alzheimer’s ...

Agreement Supports Lantheus’ Microbubble Franchise Growth Strategy and Expansion into Oncology “We are excited to collaborate with CarThera to extend our microbubble franchise into the oncology field ...

Simply sign up to the European companies myFT Digest -- delivered directly to your inbox. French scientists have carried out the first human trial of an ultrasound device that pushes drugs through the ...

The blood-brain barrier, a protective sheath surrounding the brain’s blood supply, prevents more than just germs and toxins from entering the brain — it also blocks crucial medicines that could treat ...